Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance
Reference number: TA259
Published: 27 June 2012
Last updated: 27 July 2016

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination guidance

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination guidance

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination guidance
16 May 2012
(336.73 Kb 38 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 15 May 2012